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Objectives The study sought to investigate the clinical correlates and prognostic role of anemia and changes in hemoglobin
in patients hospitalized for acute decompensated heart failure (AHF).
Background Anemia is related to a poor outcome in patients with heart failure. In addition, an increase in hemoglobin during
hospitalization might be a sign of effective decongestion and therefore related to improved outcome.
Methods This is a post hoc analysis of the PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1
Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume
Overload to Assess Treatment Effect on Congestion and Renal Function) study in 1,969 patients with AHF and
mild to moderate impaired renal function. Hemoglobin levels were measured daily for the first 4 days and at day 7.
The endpoint was 180-day all-cause mortality.
Results Anemia at baseline was observed in 50.3% of the patients. During follow-up, 359 patients (18.2%) died. Hemo-
globin increased in 69.1% and was associated with a better renal function at baseline and more weight loss, but
was associated with a deterioration of renal function (p  0.01), whereas total dose diuretics was lower in pa-
tients with hemoconcentration (p  0.01). Interaction analysis showed that greater weight loss and better base-
line renal function were associated with a more rapid increase in hemoglobin concentration (p  0.01 for both).
The absolute change in hemoglobin (g/dl) independently predicted outcome (hazard ratio: 0.66; 95% confidence
interval: 0.51 to 0.86; p  0.002), whereas baseline hemoglobin levels did not.
Conclusions Patients with AHF and preserved renal function are decongested better, as shown by an increase in hemoglobin.
A rapid increase in hemoglobin during the first week is independently associated with a favorable outcome,
despite a slight decrease in renal function. (J Am Coll Cardiol 2013;61:1973–81) © 2013 by the
American College of Cardiology Foundation
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Hemoglobin Changes in Acute Heart Failure May 14, 2013:1973–81Anemia is frequently observed in
patients with chronic heart fail-
ure (HF) (1). Prevalence of ane-
mia depends both on the severity
of HF and diagnostic criteria used to
define it, but may be as high as 50%
in selected patient cohorts. In a
recent meta-analysis, we found
that anemia was associated with a
2-fold increased mortality rate in
patients with chronic HF (2). The
etiology of anemia in HF is di-
verse, including hematinic deficien-
cies, inflammation, bone marrow
dysfunction, renal failure, and
hemodilution (3–7). In patients
with acute decompensated heart
ailure (AHF) the prevalence and consequences of anemia
re less well studied, and hemodilution may play a more
rominent role. Testani et al. (8) measured changes in
See page 1982
intracardiac pressures in 336 patients with AHF and related
this to hemoconcentration. They found that an increase in
hematocrit was associated with a significant decline in renal
function, but resulted in a better survival. Davila et al. (9)
recently studied the role of hemoconcentration in 295
patients with AHF. Hemoconcentration was significantly
associated with higher dose of diuretics, greater weight loss,
and increased risk of worsening renal function during
hospitalization. Hemoconcentration was significantly asso-
ciated with mortality in univariable analysis, but not in
multivariable analysis. However, in both studies only base-
line and discharge hemoglobin levels were studied. The aim
of the present study was to evaluate the impact of changes in
hemoglobin levels on outcome in a large well-defined cohort
of 2,033 patients with AHF, with hemoglobin levels mea-
sured at multiple pre-defined time points. Therefore, we
studied the hemoglobin trajectory of patients during the first
week after admission for AHF, including baseline hemo-
globin values, absolute changes in hemoglobin, and the
slope of the trajectory at baseline and related this to clinical
variables and outcome.
Methods
Study population. The PROTECT (Placebo-Controlled
andomized Study of the Selective Adenosine A1 Receptor
ntagonist Rolofylline for Patients Hospitalized with Acute
ecompensated Heart Failure and Volume Overload to
ssess Treatment Effect on Congestion and Renal Func-
ion) study was a multicenter, double-blind, placebo-
ontrolled study randomizing patients with AHF and mild
o moderate renal dysfunction (estimated creatinine clear-
Abbreviations
and Acronyms
AHF  acute
decompensated heart
failure
eGFR  estimated
glomerular filtration rate
EV  extracellular volume
HF  heart failure
NT-proBNP  N-terminal
pro–B-type natriuretic
peptide
NYHA  New York Heart
Association
WHO  World Health
Organizationnce 20 to 80 ml/min, using the Cockroft-Gault formula) tointravenous rolofylline or placebo within 24 h of admission
(10). For entry, patients were required to have dyspnea at
rest or minimal exertion, evidence of fluid overload requir-
ing intravenous loop diuretics, and elevated natriuretic
peptides (N-terminal pro–B-type natriuretic peptide [NT-
proBNP] 2000 pg/ml or BNP 500 pg/ml). The exclu-
sion criteria have been published previously in the design
paper (11). Patients with hemoglobin levels 8 g/dl or
hematocrit 25% or the need for blood transfusion were
excluded. Physical examination for HF signs, including
rales, edema, and jugular venous pressure were performed
prior to the initial study drug administration, daily through
discharge, and on day 7. Blood samples for measurements of
hemoglobin were taken at the time of enrollment (day 1)
and on days 2, 3, 4, and 7. Patients not surviving the first 7
days after inclusion in the study and patients with no
hemoglobin levels measured at any time point were excluded
from this analysis. This resulted in a total study population
of 1,969 patients. The primary outcome of interest for this
non-prespecified analysis of PROTECT was all-cause mor-
tality by day 180. The present study was conducted accord-
ing to the principles stated in the Declaration of Helsinki.
The study protocol was approved by the ethics committee
and institutional review boards for each participating site,
and all patients signed the informed consent form before
participation in the study.
Statistical analysis. For analysis of repeated hemoglobin
measurements, we used linear mixed-effects models (12).
Such models assume that the evolution of a patient’s
hemoglobin concentration over time can be described by a
linear regression model where some of the regression
coefficients are population specific (fixed effects) and others
are subject specific (random effects). Visual inspection of the
mean hemoglobin levels at each time point suggested that
the average evolution of hemoglobin over time was best
described by means of a quadratic function. The fixed-effect
structure therefore included an intercept, a slope for the
linear time effect, and a slope for the quadratic time effect.
The random-effect structure also included subject-specific
intercepts and slopes for the linear as well as quadratic time
effect. All analyses were on the basis of direct maximization
of the observed data likelihood, meaning that missing values
of hemoglobin were assumed to be missing at random. To
explore whether sex, age, estimated glomerular filtration rate
(eGFR), change in weight, and treatment with rolofylline were
associated with the average evolution of hemoglobin over time,
we subsequently fitted a model that included the main effects of
these clinical covariates as well as their interactions with the 2
time effects. This full model was then, in a hierarchical way,
starting with the higher order interaction terms, reduced to a
more parsimonious one by stepwise eliminating those terms
that were nonsignificant. Patients with missing covariate values
were excluded, resulting in a sample size of 1,687 patients for
the interaction analysis.
Empirical Bayes inference was applied to estimate the
subject-specific hemoglobin trajectories. On the basis of the
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May 14, 2013:1973–81 Hemoglobin Changes in Acute Heart Failureintercepts and slopes of these trajectories, patients were
classified into different groups on the basis of whether they
were anemic or nonanemic and had hemoconcentration or
no hemoconcentration. Anemia was defined, according to
the World Health Organization (WHO) criteria, as a
baseline hemoglobin level (intercept) of 13 g/dl for men
and 12 g/dl for women. Hemoconcentration was defined
as an increase in hemoglobin levels between baseline and
day 7; no hemoconcentration was defined as a hemoglobin
level that was stable or decreased between baseline and day
7. Demographic and clinical baseline characteristics, medi-
cal history, and medication use within these groups were
Baseline CharacteristicsTable 1 Baseline Characteristics
Variables
Total
(n  1,969)
Demographics
Age, yrs 70.0 11.6
Gender (% male) 67.0
Race (% white) 94.6
Measurements
Systolic BP, mm Hg 124.4 17.6
Diastolic BP, mm Hg 73.8 11.8
Heart rate, beats/min 80.0 15.4
LVEF,* % 32.2 13
Height, cm 168.5 9.2
Weight, kg 81.8 19.2
Laboratory
Hemoglobin, g/dl 12.7 1.9
Hematocrit, % 40.2 6.1
Albumin, g/dl 3.8 0.4
NT-proBNP,† pg/ml 3,000 (834)
BNP,† pg/ml 1,258 (1398)
BUN, mmol/l 34.0 17.6
Creatinine, mg/dl 1.5 0.6
eGFR, ml/min 50.6 20.2
Medical history, %
Heart failure 94.9
Ischemic heart disease 69.5
Hypertension 79.6
COPD or asthma 19.8
Diabetes mellitus 45.8
Atrial fibrillation 54.1
Treatment before admission, %
ACEI 61.9
ARB 16.1
Beta-blocker 76.7
Aldosterone blocker 44.0
Digoxin 28.4
Treatment after admission, %
Total IV loop diuretic‡ 280 (434)
Values are mean SD, proportion (%) or median (interquartile range).
admission. Data were available for 944 patients. †Either a brain natri
natriuretic peptide (NT-proBNP) level of 2,000 pg/ml or more was r
NT-proBNP was provided to study sites if needed, but measurements
values of 3,000 pg/ml. The BNP level was measured in 528 patien
of intravenous loop diuretics (in furosemide dose equivalents) adminiACEI angiotensin-converting enzyme inhibitor; ARB angiotensin recept
chronic obstructive pulmonary disease; eGFR  estimated glomerular filtratidescribed as mean  SD for normally distributed variables,
as median (interquartile range) for other continuous vari-
ables, and as percentages for categorical variables. The
distributions of continuous variables were compared by
Student t test for normally distributed variables and by
Mann-Whitney U test for non-normally distributed vari-
ables. Chi-square tests were used to compare the distribu-
tions of categorical variables.
Kaplan-Meier survival plots were constructed to describe
the effect of anemia and hemoconcentration on 180-day
mortality, and the observed differences in survival rates were
tested for by using the log-rank test. The associations
Nonanemic
(n  978)
Anemic
(n  991) p Value
68.5 11.9 71.6 11.1 0.01
63.5 70.5 0.01
96.0 93.1 0.01
124.9 17.4 124.0 17.9 0.28
76.0 11.3 71.6 12.0 0.01
82.6 15.6 77.4 14.8 0.01
30.9 12.3 33.3 13.5 0.01
168.3 9 168.8 9.5 0.21
81.0 18.8 82.5 19.7 0.08
14.2 1.3 11.2 1.1 0.01
44.5 4.8 35.9 3.9 0.01
3.9 0.4 3.8 0.4 0.01
3,000 (294) 3,000 (1410) 0.12
1,281 (1293) 1,234 (1451) 0.88
29.3 12.8 38.8 20.2 0.01
1.4 0.5 1.7 0.6 0.01
55.2 20.2 46.0 19.1 0.01
94.9 94.9 0.97
65.5 73.6 0.01
77.1 82.0 0.01
17.4 22.3 0.01
36.2 55.3 0.01
54.5 53.8 0.77
67.1 56.8 0.01
12.7 19.4 0.01
74.7 78.7 0.04
46.3 41.7 0.04
31.8 25.0 0.01
240 (340) 320 (520) 0.01
ection fraction was reported if it was available within 6 months before
eptide (BNP) level of 500 pg/ml or more or an N-terminal pro–B-type
for enrollment. A point-of-care device for measuring the level of
e than 3,000 pg/ml were not quantified, which explains the median
the NT-proBNP level was measured in 1,466 patients. ‡Total dose
from randomization through day 7 or discharge, if earlier.*The ej
uretic p
equired
of mor
ts, and
steredor blocker; BP blood pressure; BUN blood urea nitrogen; COPD
on rate; IV  intravenous; LVEF  left ventricular ejection fraction.
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Hemoglobin Changes in Acute Heart Failure May 14, 2013:1973–81between baseline hemoglobin and outcome and the absolute
change in hemoglobin between day 7 and baseline and
outcome were subsequently assessed on a continuous scale
by including both of these variables as linear terms in Cox
regression models (after possible nonlinearity in these rela-
tionships were tested for by using fractional polynomials).
To explore whether the associations between these 2 fea-
tures of the subject-specific hemoglobin profiles and 180-
day mortality were independent of other variables known to
affect outcome in AHF, the following variables were ad-
justed for in the multivariable analyses: age, creatinine,
blood urea nitrogen, systolic blood pressure, albumin, so-
Characteristics of Patients With and Without HeTable 2 Characteristics of Patients With an
Variables
Total
(n  1,969)
Demographics
Age, yrs 70.0 11.6
Gender (% male) 67.0
Measurements
Systolic BP, mm Hg 124.4 17.6
Diastolic BP, mm Hg 73.8 11.8
Heart rate, beats/min 80.0 15.4
LVEF, % 32.2 13
Height, cm 168.5 9.2
Weight, kg (baseline) 81.8 19.2
Change in weight,* kg 2.9 3.2
Change in weight,† % 3.5 3.5
Residual congestion, % 45.0
Laboratory
Hemoglobin, g/dl (baseline) 12.7 1.9
Hemoglobin, g/dl (day 7) 13.0 2.0
Change hemoglobin,‡ g/dl 0.3 0.7
Hematocrit, % (baseline) 40.2 6.1
Hematocrit, % (day 7) 41.1 6.5
Change hematocrit,‡ % 2.4 10.1
Albumin, g/dl (baseline) 3.8 0.4
Albumin, g/dl (day 7) 3.9 0.5
Change albumin,‡ % 1.2 11.2
Creatinine, mg/dl (baseline) 1.5 0.6
Creatinine, mg/dl (day 7) 1.6 0.7
Change creatinine,‡ % 5.3 26.0
eGFR, ml/min (baseline) 50.6 20.2
BUN, mmol/l (baseline) 34.0 17.6
NT-proBNP, pg/ml (baseline) 3,000 (834)
BNP, pg/ml (baseline) 1,258 (1,398)
Treatment before admission, %
ACEI 61.9
ARB 16.1
Beta-blocker 76.7
Aldosterone blocker 44.0
Digoxin 28.4
Treatment after admission (%)
Total IV loop diuretics§ 280 (434)
Rolofylline, % 66.8
Values are mean SD, proportion (%) or median (interquartile range).
in weight between day 4 and baseline (as % from baseline). ‡Chang
furosemide dose equivalents) administered from randomization through day
Abbreviations as in Table 1.dium, bicarbonate, pulmonary rales, New York Heart Asso-
ciation (NYHA) functional class 1 month before admission,
previous HF hospitalization, glucose, NT-proBNP, weight
hange between day 4 and baseline, residual congestion
presence of rales and/or edema at day 7), and diuretic dose.
YHA class was included as a categorical variable using
ummy coding. Variables that were skewed were log-
ransformed, and NT-proBNP was additionally truncated at
,000 pg/ml, the upper detection limit of the point-of-care
evice that was, if needed, provided to the study sites.
atients with missing covariate values (including all subjects
ith a BNP measurement) were excluded, resulting in a
oncentrationhout Hemoconcentration
moconcentration
(n  609)
Hemoconcentration
(n  1,360) p Value
70.3 11.9 69.9 11.4 0.51
66.2 67.4 0.58
24.5 17.3 124.4 17.8 0.92
73.8 11.7 73.8 11.9 1.0
79.7 15.9 80.1 15.2 0.63
32.2 13.4 32.2 12.9 0.99
67.9 9.4 168.8 9.1 0.05
81.2 19.3 82.0 19.2 0.37
2.3 2.9 3.1 3.3 0.01
2.8 3.4 3.7 3.6 0.01
53.2 41.1 0.01
12.7 2.0 12.6 1.8 0.39
12.3 1.9 13.2 1.9 0.01
0.4 0.4 0.6 0.5 0.01
41.2 6.3 39.7 6.0 0.01
38.3 6.1 42.4 6.3 0.01
6.2 6.5 6.8 8.7 0.01
3.9 0.5 3.8 0.4 0.01
3.7 0.4 3.9 0.4 0.01
3.9 8.2 3.6 11.7 0.01
1.6 0.6 1.5 0.6 0.01
1.6 0.7 1.6 0.7 0.15
3.1 26.4 6.4 25.8 0.01
48.3 19.5 51.6 20.4 0.01
36.5 18.9 32.9 16.8 0.01
,000 (1,071) 3,000 (697) 0.51
,303 (1,469) 1,237 (1,386) 0.41
63.1 61.4 0.50
15.3 16.4 0.52
77.3 76.5 0.67
40.6 45.5 0.04
27.4 28.8 0.52
300 (492) 260 (380) 0.01
64.7 67.8 0.18
ge in weight between day 4 and baseline (absolute change). †Change
en day 7 and baseline. §Total dose of intravenous loop diuretics (inmocd Wit
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The increase in added predictive value as a result of adding
those elements of the subject-specific hemoglobin trajecto-
ries that were significantly associated with 180-day mortal-
ity to a Cox regression model containing all the other risk
factors was examined by calculating the integrated discrim-
ination improvement.
Results
Patient characteristics. Baseline characteristics of patients
with and without anemia are shown in Table 1. According
to the WHO guidelines, 50.3% of the patients were anemic.
Hemoglobin levels 12.5 g/dl were observed in 48.2% of
the patients, whereas 7.4% of the patients were severely
anemic (hemoglobin 10.0 g/dl).
Hemoconcentration was seen in 69.1% of the patients.
able 2 shows the clinical characteristics of patients with
nd without hemoconcentration. Patients with an increase
n hemoglobin showed similar patterns in albumin and
ematocrit, which both significantly increased after 1 week
p  0.01). Weight decreased during the first 4 days by 2.9
3.2 kg and was more pronounced in patients with hemo-
concentration (p  0.01). Absolute change in hemoglobin
weakly correlated with absolute weight loss and percentage
of weight loss (both rs  –0.16, p  0.001). Hemoconcen-
tration was associated with a better renal function at
baseline. In patients with hemoconcentration, the deterio-
ration in renal function during the first week was more
pronounced compared with patients with no hemoconcen-
tration (percent change in creatinine 6.4  26 vs. 3.1 
26; p  0.01). Furthermore, in order to understand which
factors play an important role in changes in renal function,
Figure 1 Hemoglobin Changes During the First Week
Linear effects model with the average change in hemoglobin over time for the totawe investigated factors associated with changes in renal
function. Overall renal function deteriorated during the first
week in 46% of the patients. A decrease in renal function
was associated with older age (p  0.01) and lower
hemoglobin levels at baseline (p  0.01). In addition,
patients with a decrease in renal function were characterized
by a higher increase in hemoglobin levels during the first
week compared to patients with an increase in renal
function (0.38  1.2 vs. 0.16  1.1; p  0.01). Total
dose of administered diuretics was lower in patients with
hemoconcentration (p  0.01). Patients with hemocon-
centration were more often treated with rolofylline (65%
vs. 68%); however, this difference was not significant
(p  0.18).
Average evolution of hemoglobin over time. Figure 1
shows the average hemoglobin trajectory of the population.
During hospitalization, hemoglobin levels increased on
average by 0.3  0.7 g/dl during the first week. To explore
which clinical variables were associated with changes in the
hemoglobin trajectory, we performed an interaction analy-
sis. This revealed that a better baseline renal function was
significantly associated with a steeper increase of the hemo-
globin trajectory over time (p  0.02 for the interaction
between eGFR and the quadratic slope component; p 0.01 for
the interaction between eGFR and the linear slope compo-
nent). Furthermore, a greater decrease in weight during the
first 4 days of admission was associated with a steeper
increase of the hemoglobin trajectory (p  0.01 for both
interaction terms). Age, sex, and treatment with rolofylline
did not influence the average evolution of hemoglobin over
time. We did find that baseline hemoglobin levels were on
average 0.41 g/dl higher in male patients compared with
female patients (p  0.01).
rt.l coho
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During 180 days follow-up, 359 patients (18.2%) died.
Kaplan-Meier curves revealed that no anemia at baseline
and hemoconcentration were both associated with signifi-
cantly lower 180-day mortality (Figs. 2A and 2B, respec-
tively). There was no significant difference between outcome
in patients with moderate (hemoglobin: 10 to 12.5 g/dl) and
severe anemia (hemoglobin 10 g/dl; p  0.16). Baseline
hemoglobin levels and the absolute change in hemoglobin
between day 7 and baseline were associated with a reduction
Figure 2 Survival Analysis 180 Mortality
(A) Kaplan-Meier survival curve stratified for anemia at baseline. (B) Curve
stratified for the absence or presence of hemoconcentration between day 7
and baseline.in 180-day mortality in univariable Cox-regression analysis(Table 3). After including both components of the subject-
specific hemoglobin trajectories in a multivariable model
and correcting for other known risk factors in AHF, only
the absolute change in hemoglobin predicted 180-day mor-
tality (hazard ratio: 0.66; 95% confidence interval: 0.51 to
0.86; p  0.002), whereas baseline hemoglobin concentra-
tion did not. Baseline hemoglobin lost its predictive power
after adjustment for renal function and age. Figure 3 shows
the plot of the mortality risk against the change in hemo-
globin relative to a patient with stable hemoglobin levels. In
order to study the incremental predictive value, we added
change in hemoglobin to the final model (age, creatinine,
blood urea nitrogen, systolic blood pressure albumin, so-
dium, bicarbonate, pulmonary rales at baseline, NYHA
functional class 1 month before admission, previous HF
hospitalization, glucose, NT-proBNP, change in weight,
residual congestion, and diuretic dose). Absolute change in
hemoglobin improved the integrated discrimination im-
provement significantly by 1.2% (p  0.033).
Discussion
In patients admitted with AHF and renal dysfunction,
anemia at presentation is not related to a poorer outcome,
but a larger increase in hemoglobin during hospitalization is
related to improved 180-day survival. Most of the data on
anemia in heart failure are derived from cohorts of patients
with chronic HF (1, 2, 13). From these studies, we know
that anemia is common, with percentages ranging from 15%
to 50% depending on the severity of HF and the definition
of anemia. In a meta-analysis comprising 34 studies and
more than 150,000 patients, one-third of the patients were
considered anemic (2). Only a few studies have analyzed the
prevalence and consequences of anemia in patients with
AHF. Prevalence of anemia, in all studies defined as
hemoglobin 12 g/dl, ranged from 31% in the study of
Tarantini et al. (14) to 50% in the study of Young et al. (15).
The results of the present study are comparable to these
findings. Taken together, it is clear that anemia is more
prevalent in patients presenting with AHF, compared with
patients with chronic HF. However, there are discrepancies
between the different studies regarding the prognostic value
of anemia. Silva et al. (16) found that anemia in patients
with AHF is not associated with an impaired outcome,
whereas both Young et al. (15) and Tarantini et al. (14)
found an independent association with in hospital mortality
and HF readmissions. In the present study, baseline hemo-
globin levels were not independently associated with 180-
day mortality. Baseline hemoglobin concentration lost its
statistical power after adjustment for renal function and age,
emphasizing that these factors determine prognosis to a
larger extent. The reason for these differences might be
related to the endpoint, in hospital mortality versus 180-day
mortality, or the more sensitive statistical approach, hemo-
globin as a continuous variable versus a dichotomous anal-
ysis and the inclusion of the hemoglobin trajectory in the
tion, N-
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Waldum et al. (17) are in line with our findings. They
observed that in patients with severe heart failure (NYHA
functional class IIIb or IV), baseline anemia did not predict
outcome. Their population might be more comparable with
the present study.
The differences in prevalence of anemia in chronic HF
versus AHF might be related to the etiology of anemia. The
role of fluid overload in the etiology of anemia has been
established in patients with chronic HF. For example,
Westenbrink et al. showed that anemic chronic HF patients
have an elevated extracellular volume (ECV), which is
related to lower hemoglobin levels (18), especially in the
setting of impaired renal function. Impaired renal perfusion
in chronic HF causes activation of the renin-angiotensin
system, resulting in salt and fluid retention and conse-
quently increases in ECV. Furthermore, elevated levels of
Unadjusted and Adjusted HRs for 180-Day All-CTable 3 Unadjusted and Adjusted HRs for 1
Variable
Unadju
HR 95% C
Hemoglobin, per g/dl (baseline) 0.87 0.82–0
Change hemoglobin,* per g/dl 0.62 0.52–0
*Change in hemoglobin between day 7 and baseline. Adjusted hazard r
blood pressure, sodium, bicarbonate, albumin, glucose, New York He
failure hospitalization in the last year, pulmonary rales, residual conges
CI  confidence interval.
Figure 3 Mortality and Changes of Hemoglobin Levels
Plot of the mortality hazard ratio (solid line) and 95% confidence interval (dark gray aantidiuretic hormone may lead to fluid retention. This
retention of fluid in chronic HF causes hemodilution, which
may result in pseudoanemia. This pseudoanemia might even
carry a worse prognosis than in patients with true anemia
(anemic patients in which ECV levels are within the normal
range) (19). In these studies, anemic HF patients received
higher doses of diuretics but nevertheless displayed elevated
ECV. Importantly, although fluid retention was related to
anemia, signs and symptoms of fluid retention were absent.
Thus, hemodilution seems to precede the clinical presenta-
tion of fluid overload.
In the present study, the rate of hemoconcentration was
clearly associated with a greater weight loss in the first 4
days and a better renal function at baseline. The finding that
absolute levels of hemoglobin in patients with AHF do not
predict outcome suggests that anemia itself in AHF might
be mostly driven by fluid overload and that response to
Mortalityy All-Cause Mortality
Adjusted
p Value HR 95% CI p Value
0.001 0.99 0.90–1.09 0.88
0.001 0.66 0.51–0.86 0.002
Rs) are after correction of age, creatinine, blood urea nitrogen, systolic
ciation functional class 1 month prior to index hospitalization, heart
terminal pro–B-type natriuretic peptide total intravenous diuretic dose.
ainst the change in hemoglobin relative to a patient with stable hemoglobin levels.ause80-Da
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Hemoglobin Changes in Acute Heart Failure May 14, 2013:1973–81diuretics explains the finding that absolute change in hemo-
globin predicts outcome. Adenosine A1 receptor antagonists
have been studied in patients presenting with AHF. Initial
studies showed a beneficial effect on diuresis and renal protec-
tion. In 2 post hoc studies of the PROTECT trial, it was
observed that treatment with rolofylline, an adenosine A1
receptor antagonist, was associated with more weight loss
compared with placebo (20,21). However, despite a greater
weight loss, randomization to rolofylline was not associated
with an increased rate of hemoconcentration.
Study limitations. The etiology of anemia in heart failure
is diverse, and we do not have data on hematinic deficiencies
or measurements of extracellular volume. We only assessed
hemoglobin levels during the first week. Whether hemo-
globin levels remain relatively stable after this period is
unknown. Natriuretic peptides were only measured at base-
line and not during follow-up. We have no data on feeding
status of the patients. It is known that fasting or a very low
calorie diet leads to natriuresis, which may have an effect on
hemoconcentration and weight change (22). Furthermore,
we performed a post hoc analysis of the PROTECT trial
that was designed to study the effect of rolofylline in AHF
patients with renal impairment. Therefore, it remains un-
known if our findings are applicable to all patients with
AHF.
Conclusions
From the clinical perspective, besides hemoglobin measure-
ments, other bedside variables of volume status are available,
including weight change and urinary output minus intake.
The latter is notoriously unreliable in the clinical setting. In
addition, fluid balance and weight changes both reflect
intravascular as well as extravascular fluid status. In contrast,
hemoconcentration itself gives information specifically on
intravascular fluid status and one might speculate that it is
this component that in part drives the slight decrease in
renal function during decongestion. The present study
emphasizes that this moderate decrease in renal function
during decongestion does not negatively impact prognosis.
These findings are in line with the results of the DOSE
(Diuretic Optimization Strategies Evaluation) trial, which
investigated the effect of high- versus low-dose diuretics in
AHF (23). In this trial, more aggressive decongestion was
associated with a slight decrease in renal function, but
resulted in a greater relief of dyspnea and fewer serious
adverse events. However, long-term effects from this study
are unknown. The finding of our study that hemoconcen-
tration is associated with an improved outcome, despite a
slight decrease in renal function, adds to this.
Patients with AHF and preserved renal function are
decongested better, as shown by an increase in hemoglobin.
A rapid increase in hemoglobin during the first week is
independently associated with a favorable outcome, despite
a small decrease in renal function.Reprint requests and correspondence: Dr. Adriaan A. Voors,
Department of Cardiology, University Medical Center Groningen,
University of Groningen, Hanzeplein 1, 9713 GZ Groningen, the
Netherlands. E-mail: a.a.voors@umcg.nl.
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